Page 19 - TD-3-3

Tumor Discovery Immune and epigenetic therapies for TNBC

Availability of data doi: 10.1038/s41392-023-01480-x

Not applicable. 11. Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A.
Epigenetics of colorectal cancer: Biomarker and therapeutic
References potential. Nat Rev Gastroenterol Hepatol. 2020;17:111-130.

1. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, doi: 10.1038/s41575-019-0230-y
McShane LM, Allison KH. Recommendations for human 12. Dawson MA, Kouzarides T. Cancer epigenetics: From
epidermal growth factor receptor 2 testing in breast cancer. mechanism to therapy. Cell. 2012;150:12-27.
J Clin Oncol. 2013;31(31):3997-4013.
doi: 10.1016/j.cell.2012.06.013
doi: 10.5858/arpa.2018-0902-SA
13. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S,
2. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast Bergh J. Pembrolizumab for early triple-negative breast
cancer molecular subtyping and treatment progress. Breast cancer. N Engl J Med. 2020;382(9):810-821.
Cancer Res. 2020;22:61.
doi: 10.1056/NEJMoa1910549
doi: 10.1186/s13058-020-01296-5
14. Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH,
3. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Hegg R. Neoadjuvant atezolizumab in combination
Edge SB, Wong YN. Clinicopathologic features, patterns of with sequential nab-paclitaxel and anthracycline-based
recurrence, and survival among women with triple-negative chemotherapy versus placebo and chemotherapy in
breast cancer in the National Comprehensive Cancer patients with early-stage triple-negative breast cancer
Network. Cancer. 2012;118(22):5463-5472. (IMpassion031): A randomized, double-blind, phase 3 trial.
Lancet. 2020;396(10257):1090-1100.
doi: 10.1002/cncr.27581
doi: 10.1016/S0140-6736(20)31953-X
4. Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM,
Gallardo C. Pembrolizumab plus chemotherapy in 15. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. M6A
advanced triple-negative breast cancer. N Engl J Med. regulator-mediated methylation modification patterns and
2022;387(3):217-226. tumor microenvironment infiltration characterization in
gastric cancer. Mol Cancer. 2020;19(1):53.
doi: 10.1056/NEJMoa2202809
doi: 10.1186/s12943-020-01170-0
5. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K,
Oliveira M. Sacituzumab govitecan in metastatic triple- 16. Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot:
negative breast cancer. N Engl J Med. 2021;384(16):1529-1541. Firing up the tumor microenvironment. Trends Cancer.
2020;6:605-618.
doi: 10.1056/NEJMoa2028485
doi: 10.1016/j.trecan.2020.03.002
6. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin
Invest. 2007;117(4):1137-1146. 17. Zheng H, Siddharth S, Parida S, Wu X, Sharma D. Tumor
microenvironment: Key players in triple-negative breast
doi: 10.1172/JCI31405 cancer immunomodulation. Cancers (Basel). 2021;13:3357.
7. Kim R. Cancer immunoediting: From immune surveillance doi: 10.3390/cancers13163457
to immune escape. Cancer Immunother. 2007;1:1-279.
18. Bai X, Ni J, Beretov J, Graham P, Li Y. Immunotherapy for
doi: 10.1111/j.1365-2567.2007.02587.x triple-negative breast cancer: A molecular insight into the
8. Ignacio J, Manughian-Peter A, Matthew P, O’Day S, Hoon microenvironment, treatment, and resistance. J Natl Cancer
DSB, Marzese DM. Mechanisms of immune evasion in triple- Cent. 2021;1(3):75-87.
negative breast cancer patients. J Clin Oncol. 2018;36:1096. doi: 10.1016/j.jncc.2021.06.001
doi: 10.1200/JCO.2018.36.15_suppl.1096 19. Wang H, Li S, Wang Q, et al. Tumor immunological
9. Llinàs-Arias P, Íñiguez-Muñoz S, McCann K, Voorwerk L, phenotype signature-based high-throughput screening for
Orozco JIJ, Ensenyat-Mendez M. Epigenetic regulation of the discovery of combination immunotherapy compounds.
immunotherapy response in triple-negative breast cancer. Sci Adv. 2021;7(4):eabd7851.
Cancers (Basel). 2021;13(16):4139. doi: 10.1126/sciadv.abd7851
doi: 10.3390/cancers13164139 20. Petrosyan V, Dobrolecki LE, LaPlante EL, et al.
10. Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic Immunologically “cold” triple negative breast cancers
regulation in the tumor microenvironment: Molecular engraft at a higher rate in patient derived xenografts. NPJ
mechanisms and therapeutic targets. Signal Transduct Target Breast Cancer. 2022;8:104.
Ther. 2023;8:210. doi: 10.1038/s41523-022-00476-0

Volume 3 Issue 3 (2024) 13 doi: 10.36922/td.3383